 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation CDE of the China National Medical Products Administration NMPA has accepted a supplemental Biologics License Application sBLA for anti-PD-1 antibody tislelizumab in combination with chemotherapy as a first-line treatment for patients with recurrent 